Invivyd (IVVD) Income from Continuing Operations (2021 - 2026)
Invivyd's (IVVD) quarterly Income from Continuing Operations came in at 12240000.0 in Q4 2025, up 33.93% YoY from 9139298.67 in Q4 2024, and down 3.33% on a QoQ basis from 11846000.0 in Q3 2025.
Invivyd (IVVD) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of Income from Continuing Operations data on file, last reported at 12240000.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 33.93% year-over-year to 12240000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 56628000.0 (up 73.07% YoY) and the FY2025 annual result came in at 307792000.0, up 26.95% from the prior year.
- Income from Continuing Operations declined to 12240000.0 in Q4 2025, from 11846000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11846000.0 in Q3 2025 to a low of 647184000.0 in Q3 2021.
- A 5-year average of 82287400.0 and a median of 51573000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 91.74% in 2022, down 186.87% in 2022.
- Tracing IVVD's Income from Continuing Operations over 5 years: stood at 83290000.0 in 2021, then jumped by 41.88% to 48412000.0 in 2022, then sank by 57.51% to 76256000.0 in 2023, then surged by 75.71% to 18525000.0 in 2024, then jumped by 33.93% to 12240000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 12240000.0 (Q4 2025), 11846000.0 (Q3 2025), and 15420000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | -46.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -46.22 Mn |
| Dec 31, 2025 | -12.24 Mn |
| Sep 30, 2025 | -11.85 Mn |
| Jun 30, 2025 | -15.42 Mn |
| Mar 31, 2025 | -17.12 Mn |
| Dec 31, 2024 | -18.53 Mn |
| Sep 30, 2024 | -62.75 Mn |
| Jun 30, 2024 | -49.68 Mn |
| Mar 31, 2024 | -79.34 Mn |
| Dec 31, 2023 | -76.26 Mn |
| Sep 30, 2023 | -45.04 Mn |
| Jun 30, 2023 | -54.31 Mn |
| Mar 31, 2023 | -39.78 Mn |
| Dec 31, 2022 | -48.41 Mn |
| Sep 30, 2022 | -53.46 Mn |
| Jun 30, 2022 | -58.72 Mn |
| Mar 31, 2022 | -111.33 Mn |
| Dec 31, 2021 | -83.29 Mn |
| Sep 30, 2021 | -647.18 Mn |
| Jun 30, 2021 | -122.23 Mn |